J&J Headcount Reduction Program On Target; Company Posts Strong Quarter
Executive Summary
Johnson & Johnson's headcount reduction program is on target, with 1,000 employees taking advantage of an early retirement option, CFO Robert Darretta said on an April 13 conference call
You may also be interested in...
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies